Corient Private Wealth LP Purchases 1,647,315 Shares of Gossamer Bio, Inc. $GOSS

Key Points

• Corient Private Wealth LP increased its Gossamer Bio stake by 41.3% in the second quarter, purchasing 1.65 million shares to hold 5.63 million shares, or roughly 2.4% of the company. Institutional investors and hedge funds collectively own 81.23% of the stock.
• Gossamer Bio shares opened at $10.94, well below their 50-day moving average of $12.97 and 200-day average of $19.29. The stock has traded between $9.10 and $309.60 over the past year.
• Analyst opinions remain mixed, producing a consensus “Hold” rating, although the reported average price target is $256.00. Gossamer Bio is a clinical-stage biotechnology company developing seralutinib and other treatments for pulmonary and inflammatory diseases.

Corient Private Wealth LP increased its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 41.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,632,698 shares of the company's stock after purchasing an additional 1,647,315 shares during the quarter. Corient Private Wealth LP owned approximately 2.40% of Gossamer Bio worth $927,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in GOSS. Caitong International Asset Management Co. Ltd lifted its holdings in Gossamer Bio by 22.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company's stock valued at $82,000 after purchasing an additional 4,771 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Gossamer Bio by 39.6% during the fourth quarter. ProShare Advisors LLC now owns 45,338 shares of the company's stock worth $141,000 after buying an additional 12,863 shares in the last quarter. Rockefeller Capital Management L.P. raised its position in shares of Gossamer Bio by 496.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company's stock valued at $189,000 after buying an additional 50,666 shares during the last quarter. AXQ Capital LP raised its position in shares of Gossamer Bio by 36.1% in the fourth quarter. AXQ Capital LP now owns 63,117 shares of the company's stock valued at $196,000 after buying an additional 16,750 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of Gossamer Bio in the first quarter worth about $38,000. 81.23% of the stock is owned by institutional investors and hedge funds.

Gossamer Bio Stock Performance

Shares of Gossamer Bio stock opened at $10.94 on Monday. The stock has a 50 day moving average of $12.97 and a 200 day moving average of $19.29. The firm has a market capitalization of $66.84 million, a price-to-earnings ratio of -0.20 and a beta of 2.00. Gossamer Bio, Inc. has a fifty-two week low of $9.10 and a fifty-two week high of $309.60.

Analyst Ratings Changes

Several brokerages recently issued reports on GOSS. Leerink Partners raised shares of Gossamer Bio from a "market perform" rating to an "outperform" rating and set a $80.00 price objective for the company in a research note on Tuesday, July 28th. Wall Street Zen cut Gossamer Bio from a "hold" rating to a "sell" rating in a report on Sunday, September 20th. HC Wainwright reaffirmed a "buy" rating on shares of Gossamer Bio in a report on Thursday, August 27th. Finally, Weiss Ratings downgraded Gossamer Bio from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $256.00.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company's research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions.

Gossamer Bio's lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.